In our cohort, the sensitivity of ANA-IIF for CTDs, in general, was 63.3% and for SLE specifically, 64.3% which is low compared to the global figures3,9, however, there is a recent study with similar methodology which showed low sensitivity for ANA-IIF13. This evidence concerns the gene BTG3 and systemic lupus erythematosus.